Status:
COMPLETED
Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Non-squamous NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.
Detailed Description
This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.
Eligibility Criteria
Inclusion
- 18，Advanced Metastatic Non-squamous NSCLC Treatment Plan is atezolizumab-bevacizumab-carboplatin-paclitaxel
Exclusion
- Patients with contraindication of chemotherapy Pregnant or breast feeding women
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 15 2021
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05261438
Start Date
September 1 2019
End Date
September 15 2021
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013